⚕ GalenOps field
←

SITE002-0412

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-07-19

AEs
7
Serious
2
Dropout signal
–

Adverse events

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-02 (study day 2); relationship: not assessed

severe serious assessed

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-27 (study day 58); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-24 (study day 208); relationship: not assessed

severe assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-04-19 (study day 263); relationship: Y

severe assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-05-24 (study day 298); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-06-13 (study day 318); relationship: not assessed

severe serious reported

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-11-11 (study day 469); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.